Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort

TOSHIHIKO DOI,a YUTAKA FUJIWARA,c TAKAFUMI KOYAMA,c MASAFUMI IKE DA,b CHRISTOPH HELWIG,d MORIHIRO WATANABE,e YULIA VUGMEYSTER,f MASATOSHI KUDOg

Departments of aGastrointestinal Oncology and bHepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; cDepartment of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; dMerck KGaA, Darmstadt, Germany; eClinical Development Center, R&D Japan, North East Asia Hub, Merck Biopharma, Inc., Tokyo, Japan; an affiliate of Merck KGaA, Darmstadt, Germany; fEMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA; a business of Merck KGaA, Darmstadt, Germany; gDepartment of Gastroenterology and Hepatology, Kindai University Hospital, Osaka, Japan

TRIAL INFORMATION

- **ClinicalTrials.gov Identifier**: NCT02699515
- **Sponsors**: Merck KGaA, Darmstadt, Germany, and GlaxoSmithKline
- **Principal Investigator**: Toshihiko Doi
- **IRB Approved**: Yes

LESSONS LEARNED

- Bintrafusp alfa had a manageable safety profile and demonstrated preliminary clinical activity in heavily pretreated patients with solid tumors (including hepatocellular carcinoma) with no or limited treatment options.
- Findings from this study suggest bintrafusp alfa may be a novel therapeutic approach for patients with advanced solid tumors.
- Additional trials are needed to further explore safety and efficacy of bintrafusp alfa in specific tumor types.

ABSTRACT

**Background.** Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transforming growth factor-β (TGF-β) RII receptor (a TGF-β “trap”) fused to a human immunoglobulin (Ig) G1 antibody blocking programmed death-ligand 1 (PD-L1). Bintrafusp alfa is designed to neutralize TGF-β signaling by “trapping” and sequestering all TGF-β isoforms, and this trap function is physiologically linked to PD-L1 blockade in the tumor microenvironment.

**Methods.** NCT02699515 was a phase I, open-label, dose-escalation study of bintrafusp alfa (3, 10, and 20 mg/kg every 2 weeks) in Asian patients with advanced solid tumors, including a hepatocellular carcinoma (HCC) safety-assessment cohort. The primary objective was safety and tolerability; the secondary objective is best overall response.

**Results.** As of August 24, 2018, 23 patients (including 9 in the HCC cohort) received bintrafusp alfa. Eight patients experienced treatment-related adverse events (TRAEs). Three patients had grade 3 TRAEs (13.0%; hypoacusis, hyponatremia, hypopituitarism, increased blood creatine phosphokinase, and intracranial tumor hemorrhage); one had grade 4 hyponatremia (4.3%). No treatment-related deaths occurred. In the dose-escalation cohort, two patients had a confirmed partial response, and 3 had stable disease (SD), for an overall response rate of 14.3% and a disease control rate (DCR) of 35.7%. In the HCC cohort, one patient had SD (DCR, 11.1%). A dose-proportional pharmacokinetics profile was observed at doses of >3 mg/kg.

**Conclusion.** Bintrafusp alfa had a manageable safety profile and preliminary efficacy in heavily pretreated patients with advanced solid tumors, including HCC. The Oncologist 2020;25:1–11
DISCUSSION

TGF-β performs multiple, highly diverse cellular functions, which, in the context of a tumor microenvironment, can lead to stimulation of multiple relevant tumorigenic processes, including epithelial-mesenchymal transition, fibrosis, and angiogenesis [1–3]. Antibodies targeting the PD-(L)1 pathway have shown antitumor activity in a variety of indications [4, 5]. However, a majority of patients do not respond to anti-PD-(L)1 monotherapy, potentially because of insufficient generation or inadequate function of effector T cells [6]. Because their mechanisms of action are nonredundant and complementary, the simultaneous inhibition of the TGF-β and PD-(L)1 pathways may provide a novel treatment approach with the potential for increased activity.

Bintrafusp alfa (M7824) is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII receptor (a TGF-β “trap”) fused to a human IgG1 antibody blocking PD-L1. Here we report results from an ongoing phase I study (NCT02699515) designed to evaluate the safety and tolerability of bintrafusp alfa in 23 Asian patients with heavily pretreated metastatic or locally advanced solid tumors (including HCC) unselected for tumor PD-L1 expression.

Bintrafusp alfa at 3–20 mg/kg every 2 weeks (Q2W) was associated with an overall manageable safety profile. Grade 3–4 TRAEs occurred in three patients. One immune-related adverse event (grade 1 hyperthyroidism) occurred. Two patients (8.7%) experienced infusion-related reactions, which were mild and manageable. Two patients (8.7%) discontinued the study because of TRAEs. The maximum tolerated dose was not reached at the highest dose level tested in this study (20 mg/kg), and no treatment-related deaths occurred. Finally, no TGF-β–related skin adverse events were reported in the dose-escalation and HCC cohorts of this study.

The clinical activity in the 3-mg/kg and 20-mg/kg dose-escalation cohorts was consistent with antitumor activity reported in mouse models and findings of a global phase I study (NCT02517398) in which clinical activity was observed across all evaluated doses [7, 8]. Two patients in the dose-escalation component had confirmed partial response, and three had SD as their best overall response per RECIST 1.1, as assessed by the investigator, for an overall response rate of 14.3% and DCR of 35.7% (Fig. 1). Median progression-free survival and overall survival in the dose-escalation cohort were 1.4 months (95% confidence interval [CI], 0.9–6.7) and 4.8 months (95% CI, 2.1–18.6), respectively. The pharmacokinetic profile was similar to the global study [8, 9].

The ability of bintrafusp alfa to simultaneously block TGF-β and PD-L1 may contribute to the increased clinical benefit observed in heavily pretreated patients compared with historical data of other anti–PD-(L)1 agents. Although the small sample size precludes any meaningful conclusions from being drawn, the overall findings from this phase I study in Asian patients with advanced solid tumors are encouraging, and further evaluation of bintrafusp alfa in larger patient groups is warranted.

| Trial Information |
|-------------------|
| **Disease**       | Hepatocellular carcinoma |
| **Disease**       | Advanced cancer          |
| **Stage of Disease/Treatment** | Metastatic/advanced |
| **Prior Therapy** | 1 prior regimen          |
| **Type of Study** | Phase I, dose escalation and safety cohorts |
| **Primary Endpoint** | Safety |
| **Secondary Endpoints** | Best overall response, pharmacokinetics |
| **Investigator’s Analysis** | Active and should be pursued further |

© 2020 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
## Drug Information

**Drug 1**
- **Generic/Working Name**: Bintrafusp alfa
- **Company Name**: Merck KGaA, Darmstadt, Germany, and GlaxoSmithKline
- **Drug Type**: Bifunctional fusion protein
- **Drug Class**: TGF-β and PD-L1
- **Dose**: 3–20 mg/kg
- **Route**: IV
- **Schedule of Administration**: Every 2 weeks (Q2W)

## Dose Escalation Table

| Dose Level | Dose of drug: bintrafusp alfa | Number enrolled | Number evaluable for toxicity |
|------------|-------------------------------|----------------|-----------------------------|
| 1          | 3 mg/kg Q2W                   | 4              | 4                           |
| 2          | 10 mg/kg Q2W                  | 3              | 3                           |
| 3          | 20 mg/kg Q2W                  | 7              | 7                           |

## Patient Characteristics

- **Number of Patients, Male**: 11 (47.8)
- **Number of Patients, Female**: 12 (52.2)
- **Age**: Median (range): 55 (38–75)
- **Performance Status: ECOG**
  - 0 — 17
  - 1 — 6
  - 2 —
  - 3 —
  - Unknown —

## Primary Assessment Method

| Title                           | Efficacy |
|---------------------------------|----------|
| **Number of Patients Screened** | 26       |
| **Number of Patients Enrolled**  | 23       |
| **Number of Patients Evaluable for Toxicity** | 23 |
| **Number of Patients Evaluated for Efficacy** | 23 |
| **Evaluation Method**           | RECIST 1.1 |

## Adverse Events

| All Dose Levels, All Cycles Name                        | NC/NA  | 1   | 2   | 3   | 4   | 5   | All Grades |
|---------------------------------------------------------|--------|-----|-----|-----|-----|-----|------------|
| Aspartate aminotransferase increased                    | 96%    | 4%  | 0%  | 0%  | 0%  | 0%  | 4%         |
| Blood creatine phosphokinase increased                  | 91%    | 4%  | 0%  | 4%  | 0%  | 0%  | 9%         |
| Anorexia                                                | 91%    | 9%  | 0%  | 0%  | 0%  | 0%  | 9%         |
| Fatigue                                                 | 91%    | 0%  | 9%  | 0%  | 0%  | 0%  | 9%         |
| Hyponatremia                                            | 91%    | 0%  | 0%  | 4%  | 4%  | 0%  | 9%         |
| Nausea                                                  | 91%    | 4%  | 4%  | 0%  | 0%  | 0%  | 9%         |
| Fever                                                   | 91%    | 4%  | 4%  | 0%  | 0%  | 0%  | 9%         |
| Hearing impaired                                        | 96%    | 0%  | 0%  | 4%  | 0%  | 0%  | 4%         |
| Intracranial hemorrhage                                 | 96%    | 0%  | 0%  | 4%  | 0%  | 0%  | 4%         |
| Hypopituitarism                                         | 96%    | 0%  | 0%  | 4%  | 0%  | 0%  | 0%         |

Adverse events reported were TRAEs in at least two patients and/or were grade ≥3. One patient may have experienced multiple TRAEs. Abbreviation: NC/NA, no change from baseline, no adverse event reported.
SERIOUS ADVERSE EVENTS

| Name                                | Grade | Attribution |
|-------------------------------------|-------|-------------|
| Hypoacusis                          | 3     | Probable    |
| Hypopituitarism                     | 3     | Probable    |
| Ileus                               | 3     | Unrelated   |
| Nausea                              | 2     | Probable    |
| Hyperbilirubinemia                  | 3     | Unrelated   |
| Decreased appetite                  | 3     | Unrelated   |
| Hyponatremia                        | 4     | Probable    |
| Blood creatine phosphokinase increased | 3   | Probable    |
| Cancer pain                         | 2     | Unrelated   |
| Intracranial tumor hemorrhage       | 3     | Probable    |
| Malignant ascites                   | 2     | Unrelated   |
| Pulmonary hemorrhage                | 1     | Unrelated   |
| Respiratory failure                 | 5     | Unrelated   |
| Upper gastrointestinal hemorrhage   | 3     | Unrelated   |
| Pyrexia                             | 2     | Unrelated   |
| Paraneoplastic syndrome             | 3     | Unrelated   |
| Dyspnea                             | 3     | Unrelated   |
| Ascites                             | 2     | Unrelated   |
| Disease progression                 | 5     | Unrelated   |

DOSE-LIMITING TOXICITIES

| Dose level | Number enrolled | Number evaluable for toxicity | Number with a dose-limiting toxicity | Dose-limiting toxicity information |
|------------|-----------------|-------------------------------|--------------------------------------|-----------------------------------|
| 1          | 3 mg/kg Q2W     | 4                             | 0                                    | N/A                               |
| 2          | 10 mg/kg Q2W    | 3                             | 0                                    | N/A                               |
| 3          | 20 mg/kg Q2W    | 7                             | 1                                    | Intracranial tumor hemorrhage     |

Abbreviation: N/A, not applicable.

ASSESSMENT, ANALYSIS, AND DISCUSSION

Completion Study completed
Investigator’s Assessment Active and should be pursued further

Bintrafusp alfa (M7824) is a first-in-class bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor-β (TGF-β)RII (a TGF-β “trap”) fused via a flexible linker to the C terminus of each heavy chain of an immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1; anti–PD-L1) [7, 8, 10]. Preclinical data suggest that improved clinical efficacy may be observed through targeting both TGF-β and PD-(L)1 pathways compared with either pathway alone. Furthermore, as a bifunctional fusion protein, bintrafusp alfa may have improved efficacy based on the hypothesis that bintrafusp alfa binding to PD-L1 in the tumor microenvironment may facilitate local TGF-β trapping [7]. Additionally, a manageable safety profile and encouraging early signs of clinical activity have been reported with bintrafusp alfa across all doses tested (0.3–20 mg/kg) in a first-in-human global phase I, 3 + 3 dose-escalation study (NCT02517398), which enrolled patients with heavily pretreated advanced solid tumors [8]. This promising anti-tumor activity and manageable tolerability profile have also been demonstrated in multiple expansion cohorts of the same trial [11–14].

We report results of NCT02699515, an ongoing phase I, open-label, dose-escalation and dose-expansion trial of bintrafusp alfa in Asian patients with metastatic or locally advanced solid tumors. For the dose-escalation phase of this study, patients received bintrafusp alfa at 3, 10, or 20 mg/kg via 1-hour intravenous infusion every two weeks (Q2W) until confirmed progressive disease (PD), unacceptable toxicity, or trial withdrawal. Patients in the hepatocellular carcinoma (HCC) safety-assessment cohort received bintrafusp alfa 3 or 10 mg/kg Q2W intravenously until confirmed PD, unacceptable toxicity, or trial withdrawal.

© 2020 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
The primary endpoints for the trial were the occurrence of dose-limiting toxicities during the first 3 weeks of treatment in the dose-escalation part and the number, severity, and duration of treatment-related adverse events (TRAEs) according to National Cancer Institute-CTCAE v4.03. Secondary endpoints included best overall response according to RECIST 1.1 and the pharmacokinetics profile of bintrafusp alfa. Additional secondary endpoints for the HCC safety-assessment cohort were duration of response, disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Efficacy and safety were analyzed in all patients who received at least one dose of bintrafusp alfa.

Between March 17, 2016, and August 24, 2018, 26 Asian patients with metastatic or locally advanced solid tumors, including 10 with HCC, were screened; 23 patients, including 9 with HCC, were enrolled (Fig. 2) and received bintrafusp alfa Q2W at 3 mg/kg (4 and 3 patients in the dose-escalation and HCC cohort, respectively), 10 mg/kg (3 and 6 patients in the dose-escalation and HCC cohort, respectively), or 20 mg/kg (7 patients in the dose-escalation cohort).

This was a heavily pretreated population, with 64.3% of patients having received at least four prior lines of therapy (Table 1). As of the data cutoff, median duration of treatment was 5.9 weeks (range, 2–122) in the dose-escalation cohort, with one patient in the dose-escalation cohort still receiving treatment. The most common reason for discontinuation was PD (17 patients [73.9%]).

Among the 23 evaluable patients, 8 (34.8%) experienced TRAEs. Grade ≥ 3 TRAEs were observed in three patients (13.0%); grade 4 hyponatremia and grade 3 hypopituitarism; grade 3 intracranial tumor hemorrhage; and grade 3 increased blood creatine phosphokinase level, hyponatremia, and hypopituitarism. The patient with grade 4 hyponatremia also had grade 3 hypopituitarism on day 195, which led to treatment interruption; hyponatremia ultimately resolved with saline. The patient with intracranial tumor hemorrhage had a pituitary gland tumor, which is known to have an increased incidence of intrasional bleeding compared with those of other intracranial tumors [15, 16], and displayed symptoms before the study that were possibly related to this event (ongoing headache and dizziness [17]). The patient with increased blood creatine phosphokinase interrupted treatment and had grade 3 hyponatremia (on day 30); whereas the latter was ongoing at data cutoff, the increased blood creatine phosphokinase event regressed to grade 2 without medication, and treatment was resumed. On day 35, the same patient had grade 3 hypopituitarism (potentially immune-related adverse event [irAE]) that responded well to prednisolone but ultimately led to study discontinuation. Rates of irAEs, infusion-related reactions, and TRAEs leading to study discontinuation were low, with no treatment-related deaths or TGF-β-related skin adverse events in the dose-escalation and HCC cohorts.

Among the two patients with a partial response (PR), the first patient (Fig. 3A) was treated with bintrafusp alfa at 3 mg/kg and had colorectal cancer associated with Lynch syndrome [18]; this patient had a durable and ongoing response (25.0+ months) and was still receiving treatment as of the data cutoff. The second PR was documented in a patient with clear cell ovarian cancer (Fig. 3B) who received bintrafusp alfa 20 mg/kg; the PR occurred after treatment discontinuation (due to grade 3 hypoacusis), with no further anticancer therapy, persisting for 4.7 months until eventual progression due to a nontarget lesion, which was rated as PD. In the HCC safety-assessment cohort, stable disease was recorded in 1 patient, corresponding to a confirmed DCR of 11.1%. Furthermore, a median PFS of 1.3 months (95% confidence interval [CI], 0.8–2.7 months) and a median OS of 4.4 months (95% CI, 2.1–14.4 months) were observed (Fig. 4), which was comparable to that of the dose-escalation cohort (Fig. 5). In both cohorts, the unconfirmed efficacy data were identical to the confirmed data.

Overall, the pharmacokinetic profile of bintrafusp alfa in Asian patients (Table 2) was similar to that in the global study [8, 9]. Based on an integrated analysis of clinical activity and safety, the pharmacokinetic profile of bintrafusp alfa observed in the dose-escalation phase of both studies, the pharmacodynamic profile of bintrafusp alfa from the global study, and reported data from cohorts of these studies exploring 500-mg and 1200-mg Q2W dosing [12–14, 19], a dose level of 1,200 mg was evaluated in multiple additional expansion cohorts [8, 20].

Bintrafusp alfa is a bifunctional fusion protein designed to simultaneously target TGF-β and PD-L1 pathways, potentially leading to restored activation of the body’s own tumor immune responses and tumor regression. Although the small sample size precludes any meaningful conclusions from being drawn with regard to treatment outcomes, the overall findings from the present phase I study in heavily pretreated patients shows a manageable safety profile and promising preliminary efficacy in solid tumors, including HCC, with no or limited treatment options.

ACKNOWLEDGMENTS

The authors thank the patients and their families, investigators and coinvestigators, and study teams at each of the participating sites and at EMD Serono (Billerica, MA), a business of Merck KGaA (Darmstadt, Germany), and Merck KGaA (Darmstadt, Germany). This study was funded by Merck KGaA (Darmstadt, Germany) and is part of an alliance between Merck KGaA and GlaxoSmithKline. Medical writing support was provided by Marjorie Rummelt, Ph.D., ClinicalThinking Inc (Hamilton, NJ), which was also funded by Merck KGaA and GlaxoSmithKline in accordance with Good Publication Practice guidelines (http://www.ismpp.org/gpp3).

DISCLOSURES

Yutaka Fujiwara: Merck Serono, Inc, Toyko, Japan, an affiliate of Merck KGaA, Darmstadt, Germany (RF); Takafumi Koyama: Chugai, Sysmex (SAB); Masafumi Ikeda: Bayer, Eisai, Merck Sharp & Dohme, ASLAN (I/C/A), Bayer, Eisai, Ono, J-Pharma, Merck Serono, Inc, Toyko, Japan, an affiliate of Merck KGaA, Darmstadt, Germany (RF), Bayer, Eisai, Yakult (H); Christoph Helwig: Merck KGaA (E, OI); Morihiro Watanabe: Merck Serono, Inc, Toyko, Japan, an affiliate of Merck KGaA, Darmstadt, Germany (E); Yulia Vugmeyster: EMD Serono Research & Development Institute, Inc., Billerica, MA, USA; a business of Merck KGaA, Darmstadt, Germany (E, IP); Masatoshi Kudo: Bayer, Eisai, Ono, Merck Sharp & Dohme, Bristol-Myers Squibb, Eli Lilly (C/A), Daiichi Sankyo, Medico’s Hirata, Otsuka, Taiho, Astellas Pharma, Chugai, Abbvie, Bristol-Myers Squibb, EA Pharma, Takeda,

www.TheOncologist.com © 2020 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
REFERENCES

1. LI MO, Flavell RA. Contextual regulation of inflammation: A duet by transforming growth factor-β and interleukin-10. Immunity 2008;28:468–476.

2. Akhurst RJ, Hata A. Targeting the TGFβ signaling pathway in disease. Nat Rev Drug Discov 2012;11:790–811.

3. Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003;113:685–700.

4. Vanella V, Festino L, Strudel M et al. PD-L1 inhibitors in the pipeline: Promise and progress. Oncoimmunology 2018;7:e1349589.

5. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974–1982.

6. Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer 2018;118:9–16.

7. Lan Y, Zhang D, Xu C et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med 2018;10:eaaan5488.

8. Strauss J, Heery CR, Schlom J et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors. Clin Cancer Res 2018;24:1287–1295.

9. Wilkins J, Vugmeyster Y, Dussault I et al. Population pharmacokinetic analysis of bintrafusp alfa in different cancer types. Adv Ther 2019;36:2414–2433.

10. David JM, Domínguez C, McCampbell KK et al. A novel bifunctional anti-PD-L1/TGF-β trap fusion protein (M7824) efficiently reverts mesenchymalization of human NSCLC cancer cells. Oncoimmunology 2017;6:e1349589.

11. Strauss J, Gatti-Mays ME, Redman J et al. Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers. J Clin Oncol 2018;36(suppl 15):3007a.

12. Paz-Ares LG, Kim TM, Vicente Baz D et al. Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGFβ and PD-L1. J Clin Oncol 2018;36(suppl 15):9017a.

13. Barlesi F, Isambert N, Felip E et al. Initial results from phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in patients with NSCLC refractory or resistant to prior anti-PD-1/anti-PD-L1 agents. J Immunother Cancer 2017;5(suppl 2):O14a. Available at https://jtc.imbimedcentral.com/articles/10.1186/s40425-017-0289-3.

14. Kopetz S, Spira AI, Wertheim M et al. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in patients with heavily pretreated CRC: Preliminary results from a phase I trial. J Clin Oncol 2018;36(suppl 4):764a.

15. Goyal P, Utz M, Gupta N et al. Clinical and imaging features of pituitary apoplexy and role of imaging in differentiation of clinical mimics. Quant Imaging Med Surg 2018;8:219–231.

16. Wakai S, Fukushima T, Teramoto A, Sano K. Pituitary apoplexy: Its incidence and clinical significance. J Neurosurg 1981;55:187–193.

17. Giraldó EA. Intracerebral hemorrhage - Neurologic disorders. Merck Manual Professional version. Available at https://www.merckmanuals.com/professional/neurologic-disorders/stroke-cva/intracerebral-hemorrhage. Accessed September 26, 2019.

18. Rumilla K, Schowalter KV, Lindor NM et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn 2011;13:93–99.

19. Kang YK, Doi T, Kondo S et al. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in Asian patients with pretreated recurrent or refractory gastric cancer: Preliminary results from a phase I trial. J Clin Oncol 2018;36(suppl 4):100a.

20. Vugmeyster Y, Wilkins J, Harrison-Moench E et al. Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGFβ and PD-L1. J Clin Oncol 2018;36(suppl 15):2566a.

Table and Figures

Table 1: Summary of study CONSORT of the dose-escalation phase and HCC cohort of study NCT02699515.

| Screen for eligibility | Dose-escalation phase | HCC cohort |
|------------------------|-----------------------|------------|
| Screen failure | (n = 23) | (n = 10) |
| Treated with bintrafusp alfa | Safety population, n = 23 |
| Screen failure | (n = 2) | |

Figure 2. Study CONSORT of the dose-escalation phase and HCC cohort of study NCT02699515.

Abbreviation: HCC, hepatocellular carcinoma.
| Characteristic                                  | DE cohort (n = 14) | HCC cohort (n = 9) | Total (n = 23) |
|------------------------------------------------|-------------------|-------------------|---------------|
| **Sex, n (%)**                                  |                   |                   |               |
| Male                                           | 4 (28.6)          | 7 (77.8)          | 11 (47.8)     |
| Female                                         | 10 (71.4)         | 2 (22.2)          | 12 (52.2)     |
| **Age, median (range), yr**                     | 53 (38-75)        | 63 (39-71)        | 55 (38-75)    |
| **No. of prior anticancer therapies, n (%)**    |                   |                   |               |
| 0                                              | 0                 | 0                 | 0             |
| 1                                              | 0                 | 6 (66.7)          | 6 (26.1)      |
| 2                                              | 2 (14.3)          | 1 (11.1)          | 3 (13.0)      |
| 3                                              | 3 (21.4)          | 1 (11.1)          | 4 (17.4)      |
| ≥4                                             | 9 (64.3)          | 1 (11.1)          | 10 (43.5)     |
| **ECOG performance status, n (%)**             |                   |                   |               |
| 0                                              | 11 (78.6)         | 6 (66.7)          | 17 (73.9)     |
| 1                                              | 3 (21.4)          | 3 (33.3)          | 6 (26.1)      |
| **Hepatitis viral infection, n (%)**           |                   |                   |               |
| Hepatitis B                                     | 0                 | 1 (11.1)          | 1 (4.3)       |
| Hepatitis C                                     | 0                 | 6 (66.7)          | 6 (26.1)      |
| **Primary disease, n (%)**                     |                   |                   |               |
| Adenoid cystic carcinoma of the tongue          | 1 (7.1)           | 0                 | 1 (4.3)       |
| Colorectal cancer                               | 1 (7.1)           | 0                 | 1 (4.3)       |
| Descending colon cancer                        | 1 (7.1)           | 0                 | 1 (4.3)       |
| Gastric/GEJ cancer                             | 3 (21.4)          | 0                 | 3 (21.4)      |
| Hepatocellular carcinoma                       | 0                 | 9 (100.0)         | 9 (39.1)      |
| Ovarian cancer                                 | 2 (14.3)          | 0                 | 2 (14.3)      |
| Pancreatic cancer                              | 1 (7.1)           | 0                 | 1 (4.3)       |
| Parotid gland cancer                           | 1 (7.1)           | 0                 | 1 (4.3)       |
| Renal pelvis cancer                            | 1 (7.1)           | 0                 | 1 (4.3)       |
| Sigmoid colon cancer                           | 1 (7.1)           | 0                 | 1 (4.3)       |
| Stomach cancer                                 | 1 (7.1)           | 0                 | 1 (4.3)       |
| Vulvar cancer                                  | 1 (7.1)           | 0                 | 1 (4.3)       |

Abbreviations: DE, dose-escalation; ECOG, Eastern Cooperative Oncology Group; GEJ, gastroesophageal junction; HCC, hepatocellular carcinoma.
Figure 3. Scans of target lesions from patients with a partial response (PR) treated with bintrafusp alfa. Case 1: (A) patient with colon cancer who had best overall response of PR. Case 2: (B) patient with ovarian cancer with best overall response of PR.
Figure 4. Kaplan-Meier analyses in the HCC cohort. Kaplan-Meier analysis of (A) PFS assessed by the investigator and (B) OS in the HCC cohort.

Abbreviations: CI, confidence interval; HCC, hepatocellular carcinoma; OS, overall survival; PFS, progression-free survival.
**Figure 5.** Kaplan-Meier analyses in the dose-escalation cohort. Kaplan-Meier analysis of (A) progression-free survival (PFS) assessed by the investigator and (B) overall survival (OS) in the dose-escalation cohort. Abbreviations: CI, confidence interval; OS, overall survival; PFS, progression-free survival.
### Table 2. Pharmacokinetics of bintrafusp alfa after the first dose

| Dose level, mg/kg | $C_{\max}$, $\mu$g/mL | $C_{\text{max/dose}}$, (µg/mL)/(mg/kg) | $C_{\text{trough}}$, $\mu$g/mL | $C_{\text{trough/dose}}$, (µg/mL)/(mg/kg) | $\text{AUC}_{\text{tau}}$, h $\mu$g/mL | $\text{AUC}_{\text{tau/dose}}$, (h $\mu$g/mL)/(mg/kg) | $t_{1/2}$, h | CL, mL/h/kg | $V_z$, mL/kg |
|------------------|------------------------|--------------------------------------|-------------------------------|------------------------------------------|------------------------------------|-----------------------------------------------|-----------|------------|-------------|
| 3                | 54.6                   | 18.1                                 | 7.97                          | 2.64                                     | 7940                              | 2630                                           | 132       | 0.314      | 59.8        |
| %CV              | 17.9                   | 18.1                                 | 27.9                          | 28.4                                     | 16.7                              | 17.1                                           | 12.8      | 15.6       | 22.5        |
| n                | 7                      | 7                                    | 6                             | 6                                        | 7                                 | 7                                               | 7         | 7          | 7           |
| 10               | 211                    | 21.1                                 | 34.6                          | 3.46                                     | 29200                             | 2910                                           | 138       | 0.290      | 57.8        |
| %CV              | 21.7                   | 21.8                                 | 36.8                          | 36.9                                     | 25.3                              | 25.4                                           | 17.4      | 29.8       | 20.7        |
| n                | 9                      | 9                                    | 9                             | 9                                        | 8                                 | 8                                               | 7         | 7          | 7           |
| 20               | 331                    | 16.4                                 | 68.5                          | 3.39                                     | 51300                             | 2550                                           | 150       | 0.327      | 70.8        |
| %CV              | 19.2                   | 19.8                                 | 26.3                          | 26.5                                     | 24.7                              | 25.2                                           | 24.4      | 26.6       | 20.0        |
| n                | 7                      | 7                                    | 7                             | 7                                        | 7                                 | 5                                               | 5         | 5          | 5           |

Abbreviations: AUC, area under the concentration-time curve; $\text{AUC}_{\text{tau}}$, AUC over the dosing interval ($\tau = 336$ h); $C_{\max}$, maximum concentration; $C_{\text{trough}}$, trough concentration; CL, clearance; CV, coefficient of variation; GM, geometric mean; $t_{1/2}$, terminal half-life; $V_z$, volume of distribution during terminal phase mean.